<DOC>
	<DOCNO>NCT02979548</DOCNO>
	<brief_summary>The purpose study find efficacy anti-emetic drug , Aprepitant add-on therapy prevent vomit child adolescent receive chemotherapy leukemia ( AML ) . Children adolescent admit confirmed diagnosis AML assess eligibility criterion enrol study . Then divide ( randomize ) experimental control group . Experimental group receive Aprepitant capsule 1 h prior chemotherapy day 1-3 addition ondansetron . Patients require swallow whole capsule open capsule permit . All three dos administer supervision . Control group receive ondansetron ( 0.15 mg/kg ) intravenous bolus 30 minute chemotherapy follow every 8 hourly 8 day . Metoclopramide use rescue agent . The data collect patient proforma day 1 day 13 chemotherapy . A Diary maintain nausea vomiting record . Edmonton 's symptom assessment criterion use diary assess severity nausea . The NCI guideline use assess severity vomit base data provide patient diary . A modified intention-to-treat population ( patient receive chemotherapy , take one dos study drug , one post treatment measurement ) use efficacy analysis . Proportion patient complete response compare patient without aprepitant .</brief_summary>
	<brief_title>Study Evaluate Effect Aprepitant Children Adolescents Receiving AML Remission Induction Chemotherapy</brief_title>
	<detailed_description>Children adolescent admit confirmed diagnosis AML assess eligibility criterion enrol study . Subjects randomized experimental control group use table random number generate computer.Experimental group receive aprepitant capsule add-on therapy ( Apretero ; Hetero Laboratories , India ) 1 h prior chemotherapy day 1-3 addition ondansetron . The dose aprepitant per previous study base weight group ' - Weight 15-40 kg : Aprepitant 80 mg day 1-3 - Weight &gt; 41kg : Aprepitant 125 mg day 1 follow 80 mg day 2-3 Patients require swallow whole capsule open capsule permit . All three dos administer supervision sister allocate . Control group receive ondansetron ( 0.15 mg/kg ) intravenous bolus 30 minute chemotherapy follow every 8 hourly . Metoclopramide use rescue agent . The data collect patient proforma day 1 day 13 chemotherapy investigator his/her stay in-patient hospital . The Proforma contain different item deal demographic clinical characteristic subjects.A Diary maintain nausea vomiting record . It help collect data regard nausea , vomit along additional variable like- chemotherapy related toxicity , requirement rescue medication . The subject give diary symptom assessment day 1 fill supervision investigator day 1 day 2 chemotherapy . The diary give subject day 3 chemotherapy record event ( incidence severity nausea , vomiting , requirement rescue medication toxicity ) . Edmonton 's symptom assessment criterion use diary assess severity nausea . The NCI guideline use assess severity vomit base data provide patient diary.Patients/attendant 's explain filling diary maintain record vomit investigator 's supervision . A modified intention-to-treat population ( patient receive chemotherapy , take one dos study drug , one post treatment measurement ) use efficacy analysis.Proportion patient CR compare patient without aprepitant .</detailed_description>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Metoclopramide</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Antiemetics</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>1 . Newly diagnose , chemotherapyna√Øve de novo AML patient plan 3+7 remission induction chemotherapy age group 518 year 2 . Weight 15 kg ( Those able swallow medication ) 3 . Children/adolescents caregiver understand Hindi English willing participate study ( write inform consent ) 1 . Vomiting/retching within 24 h prior treatment 2 . Significant organ dysfunction ( aspartate aminotransferase/alanine aminotransferase &gt; 2.5 time upper normal limit , serum bilirubin &gt; 1.5 time upper normal limit , serum creatinine &gt; 1.5 time upper normal limit ) 3 . Patient inotropic support presentation 4 . Patient respiratory failure/mechanical ventilation presentation</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Aprepitant</keyword>
</DOC>